Valuation
- Market cap
- —
- Revenue TTM
- $0
- Net income TTM
- $0
- PE ratio
- —
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- —
Trading
- Volume
- 1,000
- Avg volume
- —
- Day's range
- $0.30 – $0.30
- Shares out
- —
- Stochastic %K
- —
- Beta
- —
- Analysts
- Strong Buy
- Price target
- —
Company profile
Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies for the treatment of cancer and autoimmune diseases. The company develops vaccines for the treatment cancer, autoimmune, and infectious diseases. Its lead product candidates include ABI-SUVA for targeting HPV16+ induced malignancies, with head, and neck cancer as the primary indication is in Phase 2 random...
Show more
Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies for the treatment of cancer and autoimmune diseases. The company develops vaccines for the treatment cancer, autoimmune, and infectious diseases. Its lead product candidates include ABI-SUVA for targeting HPV16+ induced malignancies, with head, and neck cancer as the primary indication is in Phase 2 randomized controlled trial. It also offers VB10.NEO, which is in Phase1b VB-N-02 trial; technology platform, which combines genes with desired properties to make novel compounds by creating a new code. Nykode Therapeutics AS was founded in 2006 and is headquartered in Oslo, Norway.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 47 22 95 81 93
- Website
- https://nykode.com
- Address
- Oslo Science Park, Gaustadalleen 21, Oslo, Norway
Latest news
No headlines yet.
Stocktwits
Putoelquelolea2
May 28, 2:00 PM
$VACBF There was a very strong, unjustified sale just to eliminate dividends, but there's no data that degrades the company's value, it was just an overreaction on the part of the market.
It also has no debt, which is very positive.
I see a 20% increase for next week📈✅
0 replies
MarketBeat
Aug 31, 11:15 AM
Nykode Therapeutics AS initiated by HC Wainwright at buy. www.marketbeat.com/stocks/OTCMKTS/VACBF/price-target/
$VACBF
